26 research outputs found
A Dynamical Systems Model for Combinatorial Cancer Therapy Enhances Oncolytic Adenovirus Efficacy by MEK-Inhibition
Oncolytic adenoviruses, such as ONYX-015, have been tested in clinical trials for currently untreatable tumors, but have yet to demonstrate adequate therapeutic efficacy. The extent to which viruses infect targeted cells determines the efficacy of this approach but many tumors down-regulate the Coxsackievirus and Adenovirus Receptor (CAR), rendering them less susceptible to infection. Disrupting MAPK pathway signaling by pharmacological inhibition of MEK up-regulates CAR expression, offering possible enhanced adenovirus infection. MEK inhibition, however, interferes with adenovirus replication due to resulting G1-phase cell cycle arrest. Therefore, enhanced efficacy will depend on treatment protocols that productively balance these competing effects. Predictive understanding of how to attain and enhance therapeutic efficacy of combinatorial treatment is difficult since the effects of MEK inhibitors, in conjunction with adenovirus/cell interactions, are complex nonlinear dynamic processes. We investigated combinatorial treatment strategies using a mathematical model that predicts the impact of MEK inhibition on tumor cell proliferation, ONYX-015 infection, and oncolysis. Specifically, we fit a nonlinear differential equation system to dedicated experimental data and analyzed the resulting simulations for favorable treatment strategies. Simulations predicted enhanced combinatorial therapy when both treatments were applied simultaneously; we successfully validated these predictions in an ensuing explicit test study. Further analysis revealed that a CAR-independent mechanism may be responsible for amplified virus production and cell death. We conclude that integrated computational and experimental analysis of combinatorial therapy provides a useful means to identify treatment/infection protocols that yield clinically significant oncolysis. Enhanced oncolytic therapy has the potential to dramatically improve non-surgical cancer treatment, especially in locally advanced or metastatic cases where treatment options remain limited.National Institutes of Health (U.S.) (Grant R01 CA118545)National Institutes of Health (U.S.) (Grant R01 CA095701)National Institutes of Health (U.S.) (Grant U54 CA11297)National Institutes of Health (U.S.) (Grant U54-CA112967
Mouse HORMAD1 and HORMAD2, two conserved meiotic chromosomal proteins, are depleted from synapsed chromosome axes with the help of TRIP13 AAA-ATPase
Meiotic crossovers are produced when programmed double-strand breaks (DSBs) are repaired by recombination from homologous chromosomes (homologues). In a wide variety of organisms, meiotic HORMA-domain proteins are required to direct DSB repair towards homologues. This inter-homologue bias is required for efficient homology search, homologue alignment, and crossover formation. HORMA-domain proteins are also implicated in other processes related to crossover formation, including DSB formation, inhibition of promiscuous formation of the synaptonemal complex (SC), and the meiotic prophase checkpoint that monitors both DSB processing and SCs. We examined the behavior of two previously uncharacterized meiosis-specific mouse HORMA-domain proteins-HORMAD1 and HORMAD2-in wild-type mice and in mutants defective in DSB processing or SC formation. HORMADs are preferentially associated with unsynapsed chromosome axes throughout meiotic prophase. We observe a strong negative correlation between SC formation and presence of HORMADs on axes, and a positive correlation between the presumptive sites of high checkpoint-kinase ATR activity and hyper-accumulation of HORMADs on axes. HORMADs are not depleted from chromosomes in mutants that lack SCs. In contrast, DSB formation and DSB repair are not absolutely required for depletion of HORMADs from synapsed axes. A simple interpretation of these findings is that SC formation directly or indirectly promotes depletion of HORMADs from chromosome axes. We also find that TRIP13 protein is required for reciprocal distribution of HORMADs and the SYCP1/SC-component along chromosome axes. Similarities in mouse and budding yeast meiosis suggest that TRIP13/Pch2 proteins have a conserved role in establishing mutually exclusive HORMAD-rich and synapsed chromatin domains in both mouse and yeast. Taken together, our observations raise the possibility that involvement of meiotic HORMA-domain proteins in the regulation of homologue interactions is conserved in mammals
Vasodilators in the treatment of acute heart failure: what we know, what we don’t
Although we have recently witnessed substantial progress in management and outcome of patients with chronic heart failure, acute heart failure (AHF) management and outcome have not changed over almost a generation. Vasodilators are one of the cornerstones of AHF management; however, to a large extent, none of those currently used has been examined by large, placebo-controlled, non-hemodynamic monitored, prospective randomized studies powered to assess the effects on outcomes, in addition to symptoms. In this article, we will discuss the role of vasodilators in AHF trying to point out which are the potentially best indications to their administration and which are the pitfalls which may be associated with their use. Unfortunately, most of this discussion is only partially evidence based due to lack of appropriate clinical trials. In general, we believe that vasodilators should be administered early to AHF patients with normal or high blood pressure (BP) at presentation. They should not be administered to patients with low BP since they may cause hypotension and hypoperfusion of vital organs, leading to renal and/or myocardial damage which may further worsen patients’ outcome. It is not clear whether vasodilators have a role in either patients with borderline BP at presentation (i.e., low-normal) or beyond the first 1–2 days from presentation. Given the limitations of the currently available clinical trial data, we cannot recommend any specific agent as first line therapy, although nitrates in different formulations are still the most widely used in clinical practice
Circulating microparticles: square the circle
Background: The present review summarizes current knowledge about microparticles (MPs) and provides a systematic overview of last 20 years of research on circulating MPs, with particular focus on their clinical relevance. Results: MPs are a heterogeneous population of cell-derived vesicles, with sizes ranging between 50 and 1000 nm. MPs are capable of transferring peptides, proteins, lipid components, microRNA, mRNA, and DNA from one cell to another without direct cell-to-cell contact. Growing evidence suggests that MPs present in peripheral blood and body fluids contribute to the development and progression of cancer, and are of pathophysiological relevance for autoimmune, inflammatory, infectious, cardiovascular, hematological, and other diseases. MPs have large diagnostic potential as biomarkers; however, due to current technological limitations in purification of MPs and an absence of standardized methods of MP detection, challenges remain in validating the potential of MPs as a non-invasive and early diagnostic platform. Conclusions: Improvements in the effective deciphering of MP molecular signatures will be critical not only for diagnostics, but also for the evaluation of treatment regimens and predicting disease outcomes
Recommended from our members
Molecular Mechanisms Underlying Skeletal Muscle Weakness in Human Cancer: Reduced Myosin-Actin Cross-Bridge Formation and Kinetics
PHYSICAL FUNCTION DETERIORATES substantially following a diagnosis of cancer (3, 48), and patients view this decline as one of the most distressing side effects of the disease, more so than classic side effects such as pain, nausea, and vomiting (13, 60). Functional disability can be the impetus for dose reduction or cessation of anticancer treatments and predicts chemotherapy toxicity and survival (12, 30, 33, 39). Our current understanding of the factors contributing to reduced functional capacity in patients with cancer is, however, severely limited. Physiological changes that occur within the skeletal muscle of patients with cancer can contribute to functional deterioration and physical disability. The most common adaptations believed to promote functional impairment are muscle atrophy, reduced cardiorespiratory fitness, and skeletal muscle weakness (20, 32, 54). The vast majority of studies of muscle biology in cancer have focused on signal transduction mechanisms underlying skeletal muscle atrophy (20). Understanding quantitative alterations in skeletal muscle and their mechanisms is important because they have relevance for physical function (38) and clinical outcome (18), but functional deficits persist after controlling for muscle atrophy (34, 54), and there is compelling evidence to suggest that cancer has a unique effect on the intrinsic functionality of muscle (22). In other words, a substantial proportion of the decline in physical capacity is likely explained by reductions in function per unit tissue size. Skeletal muscle contractile dysfunction has received minimal attention as a precipitant of functional changes in patients with cancer (54, 61), with the majority of studies being focused on cardiorespiratory fitness (32). However, reduced skeletal muscle contractile function is a strong predictor of decreased physical functioning in common daily activities (49) in many studies rivaling or exceeding the contribution attributed to diminished aerobic capacity (8, 51). Additionally, at a more fundamental level, the properties of the contractile elements (i.e., myofilament proteins) determine the functional character of skeletal muscle and, correspondingly, whole-body performance (24, 28, 29). As the end effectors of muscle contraction, myofilament mechanical properties necessarily set limits for muscle functionality (10). To date, no studies have evaluated the effects of cancer on myofilament protein content, structure, or functionality in humans. The goal of this study was to examine the effect of cancer on skeletal muscle contractile function at the molecular, cellular, whole-muscle, and whole-body levels. To accomplish this objective, we evaluated whole-body and whole-muscle performance using standard functional assessments and cellular/molecular structure and function on intact and chemically skinned fibers from the vastus lateralis muscle in patients with cancer and controls. Because cancer-related functional deficits are suggested to be more common in patients experiencing weight loss and during treatment (i.e., chemo/radiotherapy), we included both cachectic and noncachectic patients and patients undergoing cancer treatment. In this context, our cohort does not permit us to address the unique effect of cancer per se, but instead encompasses the effects of the disease, its treatment, and disease- and treatment-related sequelae such as weight loss. However, when discussing our findings, we refer to the effects of cancer for simplicity
The Role of Ezetimibe in the Treatment of Cardiovascular Disease
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Despite the success of treatment of CVD with statin therapy, a number of patients remain at high risk for CVD. Ezetimibe is a non-statin agent that inhibits intestinal cholesterol absorption, leading to reductions in low-density lipoprotein cholesterol (LDL-C). A number of clinical studies evaluating the use of ezetimibe therapy have resulted in discordant data regarding its safety and efficacy. In this review, we discuss the findings from these studies as well as potential indications for the use of ezetimibe for LDL-C lowering and cardiovascular event reduction